Top Markets
Coin of the day
SynAct Pharma AB SynAct Pharma AB

SynAct Pharma AB

SYNACT
Rank in Stocks #20988
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS,... SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Γ–rebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Share Price
$2.22
Last synced: 2026-08-21
Market Cap
$117.70M
Change (1 day)
2.69%
Change (1 year)
17.26%
Country
SE
Trade SynAct Pharma AB (SYNACT)

Category

Earnings for SynAct Pharma AB (SYNACT)
Earnings in 2026 TTM: 0
According to SynAct Pharma AB latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for SynAct Pharma AB from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH